OTCM
AGYTF
Market cap381mUSD
Jul 02, Last price
0.15USD
Name
Allergy Therapeutics PLC
Chart & performance
P/E
—
P/S
12.89
EPS
—
Vol. 1Y
—
Shs. 5Y
47.90%
Rev. 5Y
-6.78%
Div Yld LY
—
Div Yld TTM
—
Revenues
55m
-0.28%
Net income
-40m
L-0.21%
CFO
-29m
L-10.64%
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Allergy Therapeutics plc is a biotechnology firm dedicated to the research and development of innovative treatments for allergies. The company offers a range of injectable and sublingual immunotherapies specifically targeting allergens, alongside diagnostic tools and prescription solutions for pollen-related allergies, including those caused by grasses, weeds, and trees. Its diverse product portfolio features Pollinex Quattro, Oralvac, Venomil, ImmunoBON, Synbiotics, Acarovac Plus, Penicillin diagnostics, Pollinex, and VLP Peanut. Furthermore, Allergy Therapeutics is actively advancing new vaccine candidates designed to address sensitivities to trees, grass, house dust mites, animal dander, and peanuts. With operations spanning Central Europe, Southern Europe, the United Kingdom, and various other international markets, Allergy Therapeutics plc was established in 2004 and is headquartered in Worthing, UK.
Key people
Peter Jensen
Non-Executive Chairman of the Board · since 2023
Shaun Furlong
Chief Financial Officer, Executive Director · since 2024
Manuel Llobet
Chief Executive Officer, Executive Director · since 2009
Helge Weiner-Trapness
Executive Director, Chief Strategy Officer · since 2026
Karley Cheesman
Company Secretary · since 2023
Anthony Parker
Non-Executive Director · since 2022
Zheqing Shen
Non-Executive Director · since 2022
David Ball
Non-Executive Independent Director · since 2024
Non-Executive Independent Director · since 2021
Tunde Otulana
Senior Non-Executive Independent Director · since 2017
Lawrence Wang
Independent Non-Executive Director · since 2026
IPO date
Oct 11, 2004
Employees
622
Domiciled in
GB
Incorporated in
GB
Headquarters & legal address
DOMINION WAY
WORTHING, WSX BN14 8SA
GB
WORTHING, WSX BN14 8SA
GB
Valuation
Title GBP in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|
| 2025‑06 | 2024‑06 | 2023‑06 | 2022‑06 | 2021‑06 | 2020‑06 | 2019‑06 | 2018‑06 | 2017‑06 | |
| Income | |||||||||
Revenues | |||||||||
Cost of revenue | |||||||||
Unusual Expense (Income) | |||||||||
NOPBT | |||||||||
NOPBT Margin | |||||||||
Operating Taxes | |||||||||
Tax Rate | |||||||||
NOPAT | |||||||||
Net income | |||||||||
Dividends | |||||||||
Dividend yield | |||||||||
Proceeds from repurchase of equity | |||||||||
BB yield | |||||||||
| Debt | |||||||||
Debt current | |||||||||
Long-term debt | |||||||||
Deferred revenue | |||||||||
Other long-term liabilities | |||||||||
Net debt | |||||||||
| Cash flow | |||||||||
Cash from operating activities | |||||||||
CAPEX | |||||||||
Cash from investing activities | |||||||||
Cash from financing activities | |||||||||
FCF | |||||||||
| Balance | |||||||||
Cash | |||||||||
Long term investments | |||||||||
Excess cash | |||||||||
Stockholders' equity | |||||||||
Invested Capital | |||||||||
ROIC | |||||||||
ROCE | |||||||||
| EV | |||||||||
Common stock shares outstanding | |||||||||
Price | |||||||||
Market cap | |||||||||
EV | |||||||||
EBITDA | |||||||||
EV/EBITDA | |||||||||
Interest | |||||||||
Interest/NOPBT | |||||||||